DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
AZD1775 is an investigational drug.
There have been 51 clinical trials for AZD1775. The most recent clinical trial was a Phase 2 trial, which was initiated on March 13th 2017.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Dana-Farber Cancer Institute.
There are thirteen US patents protecting this investigational drug and one hundred and thirty-three international patents.
Recent Clinical Trials for AZD1775
|A Study of Adavosertib as Treatment for Uterine Serous Carcinoma||Parexel||Phase 2|
|A Study of Adavosertib as Treatment for Uterine Serous Carcinoma||AstraZeneca||Phase 2|
|Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for AZD1775
Top clinical trial sponsors for AZD1775
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AZD1775||Start Trial||Methods and compositions for treatment of cancer and autoimmune disease||THE JACKSON LABORATORY (Bar Harbor, ME)||Start Trial|
|AZD1775||Start Trial||Systems and methods for treating cancer||Dignity Health (San Francisco, CA) The Translational Genomics Research Institute (Phoenix, AZ)||Start Trial|
|AZD1775||Start Trial||Substituted pyrazolo[3,4-d]pyrimidinone derivatives||Banyu Pharmaceutical Co., Ltd. (Chiyoda-Ku, Tokyo, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|